Page 188 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition

importance CRITICAL CRITICAL IMPORTANT IMPORTANT IMPORTANT IMPORTANT

Quality MODERATE MODERATE LOW
– – –
Is one ACT (plus primaquine) more effective than another at treating P. vivax in areas with CQ resistant P. vivax?
391 fewer per 1000 (from 237 fewer 246 fewer per 1000 (from 69 fewer

Absolute – to 442 fewer) to 256 fewer) Not estimable – –

effect Relative risk (95% CI) – RR 0.16 (0.05–0.49) RR 0.04 (0–0.73) Not estimable – –

summary of findings no. of patients AS + AQ DHA + PPQ – 20/43 3/41 (46.5%) (7.3%) 11/43 0/42 (25.6%) (0%) 0/60 0/54 (0%) (0%) – –

considerations – – –

Other – None None – –

Imprecision – No serious imprecision 5 No serious imprecision 5 Serious 7 – –

Indirectness – Serious 4 Serious 4 Serious 4 – –

Inconsistency EFFICACy: recurrence of P . vivax parasitaemia – by day 63 – not reported 1 – Not applicable Not applicable Not applicable – –

GRADE Table A9.6.1 Quality assessment Limitations Design – – EFFICACy: recurrence of P . vivax parasitaemia – by day 42 No serious Randomized limitations 3 trial 2 EFFICACy: recurrence of P . vivax parasitaemia – by day 28 No serious Randomized limitations 3 tria l2 EFFICACy: failure to initially clear P. vivax – days 0–3 No s

174 No. of studies 0 1 1 1 1 1